Antibodies blocking PD-L1 or programmed cell death-1 (PD-1) have increased patient survival in carcinomas with significant mutational burden such as melanoma [16, 17], lung [18, 19], and bladder cancers [20, 21]. This evidence concerns the gene PDCD1 and melanoma.